CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading organization profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Organizations/education

education organization

Griffith University

AU

OPENALEX: I11701301↗ROR: 02sc3r913↗

People

Connected researchers

Alison HaywoodORCID 0000-0002-5354-8868 Arman SabetORCID 0000-0002-3469-6638 Berzenn UrbiExact authorship link Christopher IrwinORCID 0000-0002-1379-4271 Daniel ErkuORCID 0000-0002-8878-0317 Deanne H. HryciwORCID 0000-0003-1697-8890 Evelin TiralongoORCID 0000-0002-1337-0321 Gregor KijankaORCID 0000-0003-2557-234X Jennifer NgExact authorship link John FloodORCID 0000-0003-3490-0157 Katrina GethingORCID 0000-0002-7495-0792 Leanne HidesORCID 0000-0002-4550-8460 Monique LewisORCID 0000-0002-7089-7306 Olivia J. HollandORCID 0000-0002-5798-5264 Paul ScuffhamORCID 0000-0001-5931-642X Simon BroadleyORCID 0000-0002-9429-4307 Stuart A. KinnerORCID 0000-0003-3956-5343

Public evidence

11 connected articles

Feasibility, Safety and Preliminary Efficacy of 1:1 THC:CBD Cannabis Oil for Fibromyalgia Symptoms: Results From a Randomised, Double-Blind, Placebo-Controlled Pilot Trial.2026 · Europe PMC Medicinal Cannabis and Consumer Vulnerability in Australia: A Nexus of Policy and Market Factors.2025 · Europe PMC Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.2024 · Europe PMC Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.2024 · Europe PMC The predictive validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for moderate- to high-risk cannabis, methamphetamine and opioid use after release from prison.2023 · Europe PMC Exploring potential anti-inflammatory effects of medicinal cannabis.2023 · PubMed Central Open Access The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications.2021 · PubMed Central Open Access Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.2019 · PubMed Central Open Access The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids.2019 · Europe PMC

Registered research

Connected studies

A Randomised, Double-blind, Single-centre Study on the Safety, Tolerability and Efficacy of Cannabis Based Medicine Extract (MediCabilis CBD Oil) in Slowing the Disease Progression in Amyotrophic Lateral Sclerosis or Motor Neurone Disease Patientsnct03690791

Matched by exact identifiers only. Profile data: OpenAlex.

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD).

2019 · Europe PMC

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.2019 · Europe PMC

Griffith University - Medical Cannabis Research Engine